Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
Choudhury NJ, Marra A, Sui JSY, Flynn J, Yang SR, Falcon CJ, Selenica P, Schoenfeld AJ, Rekhtman N, Gomez D, Berger MF, Ladanyi M, Arcila M, Rudin CM, Riely GJ, Kris MG, Heller G, Reis-Filho JS, Yu HA. Choudhury NJ, et al. J Thorac Oncol. 2023 Apr;18(4):463-475. doi: 10.1016/j.jtho.2022.11.022. Epub 2022 Dec 6. J Thorac Oncol. 2023. PMID: 36494075 Free PMC article.
Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
Derakhshan F, Da Cruz Paula A, Selenica P, da Silva EM, Grabenstetter A, Jalali S, Gazzo AM, Dopeso H, Marra A, Brown DN, Ross DS, Mandelker D, Razavi P, Chandarlapaty S, Wen HY, Brogi E, Zhang H, Weigelt B, Pareja F, Reis-Filho JS. Derakhshan F, et al. Mod Pathol. 2024 Feb;37(2):100375. doi: 10.1016/j.modpat.2023.100375. Epub 2023 Nov 3. Mod Pathol. 2024. PMID: 37925055
APOBEC3 mutagenesis drives therapy resistance in breast cancer.
Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva EM, Brown DN, Zhu Y, Patel J, Blanco-Heredia J, Stefanovska B, Carpenter MA, Pei X, Frosina D, Jungbluth AA, Ladanyi M, Curigliano G, Weigelt B, Riaz N, Powell SN, Razavi P, Harris RS, Reis-Filho JS, Marra A, Chandarlapaty S. Gupta A, et al. bioRxiv [Preprint]. 2024 May 1:2024.04.29.591453. doi: 10.1101/2024.04.29.591453. bioRxiv. 2024. PMID: 38746158 Free PMC article. Preprint.
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Huerga Sanchez I, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Kudo R, et al. Among authors: reis filho js. Cancer Cell. 2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. Epub 2024 Oct 10. Cancer Cell. 2024. PMID: 39393354 Free article.
Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations.
Dopeso H, Gazzo AM, Derakhshan F, Brown DN, Selenica P, Jalali S, Da Cruz Paula A, Marra A, da Silva EM, Basili T, Gusain L, Colon-Cartagena L, Bhaloo SI, Green H, Vanderbilt C, Oesterreich S, Grabenstetter A, Kuba MG, Ross D, Giri D, Wen HY, Zhang H, Brogi E, Weigelt B, Pareja F, Reis-Filho JS. Dopeso H, et al. NPJ Precis Oncol. 2024 Feb 12;8(1):33. doi: 10.1038/s41698-024-00508-x. NPJ Precis Oncol. 2024. PMID: 38347189 Free PMC article.
Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors.
Zhu Y, Pei X, Novaj A, Setton J, Bronder D, Derakhshan F, Selenica P, McDermott N, Orman M, Plum S, Subramanyan S, Braverman SH, McMillan B, Sinha S, Ma J, Gazzo A, Khan A, Bakhoum S, Powell SN, Reis-Filho JS, Riaz N. Zhu Y, et al. Among authors: reis filho js. Genome Med. 2024 Aug 28;16(1):108. doi: 10.1186/s13073-024-01371-y. Genome Med. 2024. PMID: 39198848 Free PMC article.
645 results